Charles Ruetsch, PhD

Implementing a claims-based algorithm and disease management program may be an effective strategy to reduce relapse and cost among patients with schizophrenia.

Patient and treatment heterogeneity were characterized within a sample of nonadherent buprenorphine members; an improved understanding of these factors may optimize patient—treatment matching and intervention efforts.

A large proportion of opioid analgesic treated chronic pain patients exhibited behaviors indicative of potentially problematic opioid use, which significantly affected healthcare costs.